nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

26.10.2016 | Original Paper

Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies

verfasst von: Ilja Spellmann, Rebecca Schennach, Florian Seemüller, Sebastian Meyer, Richard Musil, Markus Jäger, Max Schmauß, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G. Schmidt, Wolfgang Gaebel, Joachim Klosterkötter, Isabella Heuser, Michael Bauer, Mazda Adli, Joachim Zeiler, Wolfram Bender, Klaus-Thomas Kronmüller, Marcus Ising, Peter Brieger, Wolfgang Maier, Matthias R. Lemke, Eckart Rüther, Stefan Klingberg, Markus Gastpar, Michael Riedel, Hans-Jürgen Möller

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The objective of the present study was the application and comparison of common remission and recovery criteria between patients with the diagnosis of schizophrenia and major depressive disorder (MDD) under inclusion of other outcome parameters. Patients with schizophrenia and MDD who were treated as inpatients at the beginning of the study were examined within two naturalistic follow-up trials from admission to discharge of an inpatient treatment period and the one-year follow-up assessment. PANSS criteria of the Remission in Schizophrenia Working Group (RSWG) for schizophrenia and HAMD criteria of the ACNP Task Force in MDD for depressive patients as well as the Clinical Global Impression-Severity Scale (CGI-S) were applied as symptomatic outcome measures additionally to functional outcome parameters. Data of 153 schizophrenia patients and 231 patients with a MDD episode have been included in the analysis. More depressive than schizophrenia patients reached a threshold score of ≤3 on the CGI-S, indicating symptomatic remission at discharge and at the one-year follow-up. In contrast similar proportions of patients reaching symptomatic remission at discharge from inpatient treatment and at the one-year follow-up in the schizophrenia and in the MDD group were found when disease-related consensus criteria (RSWG vs. ACNP Task Force) were used. Functional remission and recovery rates were significantly lower in schizophrenia than in depressive patients at the one-year follow-up visit. Common outcome criteria for remission and recovery in schizophrenia and major depression were not directly comparable. However, our results indicated a significantly poorer outcome in schizophrenia than in depressive patients according to terms of remission and recovery.

Moller HJ (2008) Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin’s dichotomy and beyond. Eur Arch Psychiatry Clin Neurosci 258(Suppl 2):48–73. doi:10.1007/s00406-008-2004-3 CrossRefPubMed

Moller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2010) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci 260(5):367–384. doi:10.1007/s00406-010-0117-y CrossRefPubMed

Moller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2011) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: assessing courses, types and time stability of diagnostic classification. Eur Psychiatry 26(4):231–243. doi:10.1016/j.eurpsy.2010.04.012 CrossRefPubMed

Harrow M, Grossman LS, Herbener ES, Davies EW (2000) Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry 177:421–426CrossRefPubMed

Craddock N, Owen MJ (2005) The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry 186:364–366. doi:10.1192/bjp.186.5.364 CrossRefPubMed

Craddock N, Owen MJ (2010) The Kraepelinian dichotomy—going, going… but still not gone. Br J Psychiatry 196(2):92–95. doi:10.1192/bjp.bp.109.073429 CrossRefPubMedPubMedCentral

Moskvina V, Craddock N, Holmans P, Nikolov I, Pahwa JS, Green E, Owen MJ, O’Donovan MC (2009) Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 14(3):252–260. doi:10.1038/mp.2008.133 CrossRefPubMed

O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CC, Howie B, Leung HT, Hartmann AM, Moller HJ, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Williams NM, Giegling I, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Gejman PV, Cichon S, Nothen MM, Gill M, Corvin A, Rujescu D, Kirov G, Owen MJ, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Cloninger CR (2008) Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 40(9):1053–1055. doi:10.1038/ng.201 CrossRefPubMed

Peerbooms OL, van Os J, Drukker M, Kenis G, Hoogveld L, de Hert M, Delespaul P, van Winkel R, Rutten BP (2011) Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun 25(8):1530–1543. doi:10.1016/j.bbi.2010.12.006 CrossRefPubMed

10.

Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460(7256):748–752. doi:10.1038/nature08185 PubMed

11.

Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium (2015) Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 18(2):199–209. doi: 10.1038/nn.3922

12.

Hafner H, Maurer K, Trendler G, an der Heiden W, Schmidt M, Konnecke R (2005) Schizophrenia and depression: challenging the paradigm of two separate diseases–a controlled study of schizophrenia, depression and healthy controls. Schizophr Res 77(1):11–24. doi:10.1016/j.schres.2005.01.004 CrossRefPubMed

13.

Moller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W (2015) DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences–part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci 265(1):5–18. doi:10.1007/s00406-014-0520-x CrossRefPubMed

14.

Moller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Barnikol UB, Lista S, Severus E, Maier W (2015) DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci 265(2):87–106. doi:10.1007/s00406-014-0521-9 CrossRefPubMed

15.

Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162(3):441–449. doi:10.1176/appi.ajp.162.3.441 CrossRefPubMed

16.

Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF (2006) Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 31(9):1841–1853. doi:10.1038/sj.npp.1301131 CrossRefPubMed

17.

Corrigan PW (2006) Recovery from schizophrenia and the role of evidence-based psychosocial interventions. Expert Rev Neurother 6(7):993–1004. doi:10.1586/14737175.6.7.993 CrossRefPubMed

18.

Liberman RP, Kopelowicz A (2005) Recovery from schizophrenia: a concept in search of research. Psychiatr Serv 56(6):735–742. doi:10.1176/appi.ps.56.6.735 CrossRefPubMed

19.

Greer TL, Kurian BT, Trivedi MH (2010) Defining and measuring functional recovery from depression. CNS Drugs 24(4):267–284. doi:10.2165/11530230-000000000-00000 CrossRefPubMed

20.

Wittchen HUWU, Gruschwitz S, Zaudig M (1997) Structured clinical interview for DSM-IV. Hogrefe, Göttingen

21.

Cording CGW, Spengler A (1995) The new psychiatric basic documentation. A recommendation by the DGPPN for quality assurance in inpatient treatment. Spektrum Psychiatrie Nervenheilkunde 24:3–41

22.

Guy W (1976) ECDEU Assessment Manual for Psychopharmacology—Revised (DHEW Publ No ADM 76–338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, pp 218–222

23.

Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23(1):99–110CrossRefPubMed

24.

Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6(4):278–296CrossRefPubMed

25.

Patterson DA, Lee MS (1995) Field trial of the global assessment of functioning scale-modified. Am J Psychiatry 152(9):1386–1388CrossRefPubMed

26.

Roy-Byrne P, Dagadakis C, Unutzer J, Ries R (1996) Evidence for limited validity of the revised global assessment of functioning scale. Psychiatr Serv 47(8):864–866CrossRefPubMed

27.

Leucht S (2014) Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 75(Suppl 1):8–14. doi:10.4088/JCP.13049su1c.02 CrossRefPubMed

28.

Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM (2003) A typical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine versus chlorpromazine. Neuropsychopharmacology 28(5):995–1003. doi:10.1038/sj.npp.1300157 PubMed

29.

Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50(5):369–376CrossRefPubMed

30.

Schennach-Wolff R, Moller HJ, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Riedel M (2010) A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Pharmacopsychiatry 43(7):245–251. doi:10.1055/s-0030-1262788 CrossRefPubMed

31.

Pinna F, Tusconi M, Bosia M, Cavallaro R, Carpiniello B (2013) Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry 13(1):235. doi:10.1186/1471-244x-13-235 CrossRefPubMedPubMedCentral

32.

Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D (2010) Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci 12(3):393–407PubMedPubMedCentral

33.

Marneros A, Deister A, Rohde A (1992) Comparison of long-term outcome of schizophrenic, affective and schizoaffective disorders. Br J Psychiatry Suppl 18:44–51

34.

Marneros A, Rohde A, Deister A (1998) Frequency and phenomenology of persisting alterations in affective, schizoaffective and schizophrenic disorders: a comparison. Psychopathology 31(1):23–28CrossRefPubMed

35.

Bottlender R, Strauss A, Moller HJ (2013) Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders. Eur Arch Psychiatry Clin Neurosci 263(2):85–92. doi:10.1007/s00406-012-0335-6 CrossRefPubMed

36.

Harrow M, Grossman LS, Jobe TH, Herbener ES (2005) Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr Bull 31(3):723–734. doi:10.1093/schbul/sbi026 CrossRefPubMed

37.

Bottlender R, Strauss A, Moller HJ (2010) Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. Schizophr Res 116(1):9–15. doi:10.1016/j.schres.2009.10.008 CrossRefPubMed

38.

McGlashan TH (1984) The chestnut lodge follow-up study. I. Follow-up methodology and study sample. Arch Gen Psychiatry 41(6):573–585CrossRefPubMed

39.

Tsuang MT, Woolson RF, Winokur G, Crowe RR (1981) Stability of psychiatric diagnosis. Schizophrenia and affective disorders followed up over a 30- to 40-year period. Arch Gen Psychiatry 38(5):535–539CrossRefPubMed

40.

Moller HJ, Hohe-Schramm M, Cording-Tommel C, Schmid-Bode W, Wittchen HU, Zaudig M, von Zerssen D (1989) The classification of functional psychoses and its implications for prognosis. Br J Psychiatry 154:467–472CrossRefPubMed

41.

Moller HJ, Schmid-Bode W, Cording-Tommel C, Wittchen HU, Zaudig M, von Zerssen D (1988) Psychopathological and social outcome in schizophrenia versus affective/schizoaffective psychoses and prediction of poor outcome in schizophrenia. Results from a 5–8 year follow-up. Acta Psychiatr Scand 77(4):379–389CrossRefPubMed

42.

Lasser RA, Bossie CA, Gharabawi GM, Kane JM (2005) Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 77(2–3):215–227. doi:10.1016/j.schres.2005.03.006 CrossRefPubMed

43.

Sethuraman G, Taylor CC, Enerson M, Dunayevich E (2005) A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res 79(2–3):337–340. doi:10.1016/j.schres.2005.06.015 CrossRefPubMed

44.

Petersen L, Nordentoft M, Jeppesen P, Ohlenschaeger J, Thorup A, Christensen TO, Krarup G, Dahlstrom J, Haastrup B, Jorgensen P (2005) Improving 1-year outcome in first-episode psychosis: OPUS trial. Br J Psychiatry Suppl 48:s98–103. doi:10.1192/bjp.187.48.s98 CrossRefPubMed

Titel: Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies
verfasst von: Ilja Spellmann
Rebecca Schennach
Florian Seemüller
Sebastian Meyer
Richard Musil
Markus Jäger
Max Schmauß
Gerd Laux
Herbert Pfeiffer
Dieter Naber
Lutz G. Schmidt
Wolfgang Gaebel
Joachim Klosterkötter
Isabella Heuser
Michael Bauer
Mazda Adli
Joachim Zeiler
Wolfram Bender
Klaus-Thomas Kronmüller
Marcus Ising
Peter Brieger
Wolfgang Maier
Matthias R. Lemke
Eckart Rüther
Stefan Klingberg
Markus Gastpar
Michael Riedel
Hans-Jürgen Möller
Publikationsdatum: 26.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 4/2017
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-016-0741-2

Neu im Fachgebiet Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies

Abstract

Neu im Fachgebiet Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Delir kann Demenz begünstigen

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Stigmatization of psychiatric symptoms and psychiatric service use: a vignette-based representative population survey

The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study

A trans-diagnostic approach to psychosis, psychiatric medication nomenclature and stigma

Treatment recommendations for schizophrenia, major depression and alcohol dependence and stigmatizing attitudes of the public: results from a German population survey

Self-stigma and suicidality: a longitudinal study

Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP)

Neu im Fachgebiet Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Delir kann Demenz begünstigen

Zunahme von Geschlechtsinkongruenz und -dysphorie registriert

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Psychiatrie